217 related articles for article (PubMed ID: 24897507)
1. Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors.
Wichmann C; Quagliano-Lo Coco I; Yildiz Ö; Chen-Wichmann L; Weber H; Syzonenko T; Döring C; Brendel C; Ponnusamy K; Kinner A; Brandts C; Henschler R; Grez M
Leukemia; 2015 Feb; 29(2):279-89. PubMed ID: 24897507
[TBL] [Abstract][Full Text] [Related]
2. Distinct classes of c-Kit-activating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia.
Nick HJ; Kim HG; Chang CW; Harris KW; Reddy V; Klug CA
Blood; 2012 Feb; 119(6):1522-31. PubMed ID: 21937700
[TBL] [Abstract][Full Text] [Related]
3. Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells.
Zheng X; Oancea C; Henschler R; Ruthardt M
Int J Oncol; 2009 Jun; 34(6):1521-31. PubMed ID: 19424569
[TBL] [Abstract][Full Text] [Related]
4. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice.
Wang YY; Zhao LJ; Wu CF; Liu P; Shi L; Liang Y; Xiong SM; Mi JQ; Chen Z; Ren R; Chen SJ
Proc Natl Acad Sci U S A; 2011 Feb; 108(6):2450-5. PubMed ID: 21262832
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes.
Mitkevich VA; Petrushanko IY; Spirin PV; Fedorova TV; Kretova OV; Tchurikov NA; Prassolov VS; Ilinskaya ON; Makarov AA
Cell Cycle; 2011 Dec; 10(23):4090-7. PubMed ID: 22101339
[TBL] [Abstract][Full Text] [Related]
6. An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice.
Grisolano JL; O'Neal J; Cain J; Tomasson MH
Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9506-11. PubMed ID: 12881486
[TBL] [Abstract][Full Text] [Related]
7. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Schnittger S; Kohl TM; Haferlach T; Kern W; Hiddemann W; Spiekermann K; Schoch C
Blood; 2006 Mar; 107(5):1791-9. PubMed ID: 16254134
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of microRNAs 222/221 in acute myelogenous leukemia with deranged core-binding factor subunits.
Brioschi M; Fischer J; Cairoli R; Rossetti S; Pezzetti L; Nichelatti M; Turrini M; Corlazzoli F; Scarpati B; Morra E; Sacchi N; Beghini A
Neoplasia; 2010 Nov; 12(11):866-76. PubMed ID: 21076613
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
[TBL] [Abstract][Full Text] [Related]
10. Activated leukemic oncogenes AML1-ETO and c-kit: role in development of acute myeloid leukemia and current approaches for their inhibition.
Rulina AV; Spirin PV; Prassolov VS
Biochemistry (Mosc); 2010 Dec; 75(13):1650-66. PubMed ID: 21417999
[TBL] [Abstract][Full Text] [Related]
11. A histone acetyltransferase p300 inhibitor C646 induces cell cycle arrest and apoptosis selectively in AML1-ETO-positive AML cells.
Gao XN; Lin J; Ning QY; Gao L; Yao YS; Zhou JH; Li YH; Wang LL; Yu L
PLoS One; 2013; 8(2):e55481. PubMed ID: 23390536
[TBL] [Abstract][Full Text] [Related]
12. Thrombopoietin/MPL participates in initiating and maintaining RUNX1-ETO acute myeloid leukemia via PI3K/AKT signaling.
Pulikkan JA; Madera D; Xue L; Bradley P; Landrette SF; Kuo YH; Abbas S; Zhu LJ; Valk P; Castilla LH
Blood; 2012 Jul; 120(4):868-79. PubMed ID: 22613795
[TBL] [Abstract][Full Text] [Related]
13. Compatibility of RUNX1/ETO fusion protein modules driving CD34+ human progenitor cell expansion.
Chen-Wichmann L; Shvartsman M; Preiss C; Hockings C; Windisch R; Redondo Monte E; Leubolt G; Spiekermann K; Lausen J; Brendel C; Grez M; Greif PA; Wichmann C
Oncogene; 2019 Jan; 38(2):261-272. PubMed ID: 30093631
[TBL] [Abstract][Full Text] [Related]
14. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
[TBL] [Abstract][Full Text] [Related]
15. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
[TBL] [Abstract][Full Text] [Related]
16. The RUNX1-ETO fusion protein trans-activates c-KIT expression by recruiting histone acetyltransferase P300 on its promoter.
Chen G; Liu A; Xu Y; Gao L; Jiang M; Li Y; Lv N; Zhou L; Wang L; Yu L; Li Y
FEBS J; 2019 Mar; 286(5):901-912. PubMed ID: 30637949
[TBL] [Abstract][Full Text] [Related]
17. RUNX1/ETO and mutant KIT both contribute to programming the transcriptional and chromatin landscape in t(8;21) acute myeloid leukemia.
Chin PS; Assi SA; Ptasinska A; Imperato MR; Cockerill PN; Bonifer C
Exp Hematol; 2020 Dec; 92():62-74. PubMed ID: 33152396
[TBL] [Abstract][Full Text] [Related]
18. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia.
Kuchenbauer F; Feuring-Buske M; Buske C
Cell Cycle; 2005 Dec; 4(12):1716-8. PubMed ID: 16294039
[TBL] [Abstract][Full Text] [Related]
19. The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice.
Schessl C; Rawat VP; Cusan M; Deshpande A; Kohl TM; Rosten PM; Spiekermann K; Humphries RK; Schnittger S; Kern W; Hiddemann W; Quintanilla-Martinez L; Bohlander SK; Feuring-Buske M; Buske C
J Clin Invest; 2005 Aug; 115(8):2159-68. PubMed ID: 16025155
[TBL] [Abstract][Full Text] [Related]
20. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells.
Wichmann C; Chen L; Heinrich M; Baus D; Pfitzner E; Zörnig M; Ottmann OG; Grez M
Cancer Res; 2007 Mar; 67(5):2280-9. PubMed ID: 17332359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
